Status:
COMPLETED
Mesoglycan for Pain Control After Open Excisional HAEMOrrhoidectomy
Lead Sponsor:
Societa Italiana di Chirurgia ColoRettale
Collaborating Sponsors:
Gaetano Gallo
Giuseppe Sammarco
Conditions:
Haemorrhoidal Disease
Post-operative Pain
Brief Summary
Haemorrhoidal disease (HD) is the most common proctological disease, with a prevalence that can reach up to 39% of the population. Although I and II degree HD can be treated successfully with medical ...
Detailed Description
This was a retrospective multicentre study and is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies Between Septembe...
Eligibility Criteria
Inclusion
- III and IV degree Hemorrhoidal Disease
- Age \> 18
- Written Informed Consent
Exclusion
- Age \<18
- Past or present history of:
- Coagulopathy
- Cardiac Diseases
- Anticoagulant Therapies
- Colorectal or Anal Neoplasms
- Inflammatory Bowel Disease
- Pelvic Radiotherapy
- Anal Surgery
- Allergy to Mesoglycan
- Inability to return for post-operative control visits
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT04481698
Start Date
April 1 2017
End Date
December 1 2017
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Catanzaro
Catanzaro, Italy, 88100